Preliminary results of propranolol treatment for patients with infantile hemangioma
Propranolol, a non-selective beta-blocker, has recently been introduced as a treatment for infantile hemangiomas. In this study, we evaluated the effect of propranolol in 12 infants with hemangioma. Twelve infants (9 girls) with a median age of 4.5 months were included in the study. All of th...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2011-04-01
|
| Series: | The Turkish Journal of Pediatrics |
| Online Access: | https://turkjpediatr.org/article/view/1741 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025202988089344 |
|---|---|
| author | Funda Corapcioğlu Sema Büyükkapu-Bay Köksal Binnetoğlu Abdulkadir Babaoğlu Yonca Anik Melih Tugay |
| author_facet | Funda Corapcioğlu Sema Büyükkapu-Bay Köksal Binnetoğlu Abdulkadir Babaoğlu Yonca Anik Melih Tugay |
| author_sort | Funda Corapcioğlu |
| collection | DOAJ |
| description |
Propranolol, a non-selective beta-blocker, has recently been introduced as a treatment for infantile hemangiomas. In this study, we evaluated the effect of propranolol in 12 infants with hemangioma. Twelve infants (9 girls) with a median age of 4.5 months were included in the study. All of the patients in the study group received short-term (1-9 weeks, median: 4 weeks) systemic corticosteroids as a first-line therapy. All patients received propranolol 2 mg/kg/day, divided into three doses. They were treated in an inpatient setting for the first 72 hours of the treatment. Vital signs, blood pressure and blood glucose were monitored. Propranolol treatment was given for 4-9 months (median: 5 months). In the study group, regression rate of the mean dimension of the lesion was 38% +/- 15 (range 15%-50, median 45%) at the 2nd month of therapy. Over 9 months, which was the maximum follow-up period, the regression rate of the mean dimension of the lesion was 55% +/- 31 (range 20%-80, median 50%). One patient had transient bradycardia, which improved spontaneously. No other side effect was observed in the study population. Propranolol appears to be an effective drug for infantile hemangiomas with good clinical tolerance. We suggest that propranolol is the preferable drug as the first-line therapy for infantile hemangiomas.
|
| format | Article |
| id | doaj-art-795a6f7fbd954019a664e74335da2db5 |
| institution | DOAJ |
| issn | 0041-4301 2791-6421 |
| language | English |
| publishDate | 2011-04-01 |
| publisher | Hacettepe University Institute of Child Health |
| record_format | Article |
| series | The Turkish Journal of Pediatrics |
| spelling | doaj-art-795a6f7fbd954019a664e74335da2db52025-08-20T03:00:54ZengHacettepe University Institute of Child HealthThe Turkish Journal of Pediatrics0041-43012791-64212011-04-01532Preliminary results of propranolol treatment for patients with infantile hemangiomaFunda Corapcioğlu0Sema Büyükkapu-BayKöksal BinnetoğluAbdulkadir BabaoğluYonca AnikMelih TugayDepartment of Pediatrics, Kocaeli University Faculty of Medicine, Kocaeli, Turkey. Propranolol, a non-selective beta-blocker, has recently been introduced as a treatment for infantile hemangiomas. In this study, we evaluated the effect of propranolol in 12 infants with hemangioma. Twelve infants (9 girls) with a median age of 4.5 months were included in the study. All of the patients in the study group received short-term (1-9 weeks, median: 4 weeks) systemic corticosteroids as a first-line therapy. All patients received propranolol 2 mg/kg/day, divided into three doses. They were treated in an inpatient setting for the first 72 hours of the treatment. Vital signs, blood pressure and blood glucose were monitored. Propranolol treatment was given for 4-9 months (median: 5 months). In the study group, regression rate of the mean dimension of the lesion was 38% +/- 15 (range 15%-50, median 45%) at the 2nd month of therapy. Over 9 months, which was the maximum follow-up period, the regression rate of the mean dimension of the lesion was 55% +/- 31 (range 20%-80, median 50%). One patient had transient bradycardia, which improved spontaneously. No other side effect was observed in the study population. Propranolol appears to be an effective drug for infantile hemangiomas with good clinical tolerance. We suggest that propranolol is the preferable drug as the first-line therapy for infantile hemangiomas. https://turkjpediatr.org/article/view/1741 |
| spellingShingle | Funda Corapcioğlu Sema Büyükkapu-Bay Köksal Binnetoğlu Abdulkadir Babaoğlu Yonca Anik Melih Tugay Preliminary results of propranolol treatment for patients with infantile hemangioma The Turkish Journal of Pediatrics |
| title | Preliminary results of propranolol treatment for patients with infantile hemangioma |
| title_full | Preliminary results of propranolol treatment for patients with infantile hemangioma |
| title_fullStr | Preliminary results of propranolol treatment for patients with infantile hemangioma |
| title_full_unstemmed | Preliminary results of propranolol treatment for patients with infantile hemangioma |
| title_short | Preliminary results of propranolol treatment for patients with infantile hemangioma |
| title_sort | preliminary results of propranolol treatment for patients with infantile hemangioma |
| url | https://turkjpediatr.org/article/view/1741 |
| work_keys_str_mv | AT fundacorapcioglu preliminaryresultsofpropranololtreatmentforpatientswithinfantilehemangioma AT semabuyukkapubay preliminaryresultsofpropranololtreatmentforpatientswithinfantilehemangioma AT koksalbinnetoglu preliminaryresultsofpropranololtreatmentforpatientswithinfantilehemangioma AT abdulkadirbabaoglu preliminaryresultsofpropranololtreatmentforpatientswithinfantilehemangioma AT yoncaanik preliminaryresultsofpropranololtreatmentforpatientswithinfantilehemangioma AT melihtugay preliminaryresultsofpropranololtreatmentforpatientswithinfantilehemangioma |